Ascelia Pharma AB (publ) (ACE) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome everyone to the webcast for Acelia Pharma's Q4 report for 2025. On this call, we will be making forward-looking statements. On today's call, we will start with an overview of Acelia Pharma, recent key events, and then head into the portfolio update before moving on to financials and priorities ahead. After the presentation, we will open up for questions as usual. I'm Magnus Corfertsen, CEO of Acelia Pharma. And with me today, I have Julie Varas Brogren, Deputy CEO, Andreas Norlin, Chief Scientific Officer, and Anton Hansson, CFO. I'm pleased to welcome Anton to his first quarterly call as Chief Financial Officer. This will also be the last quarterly call with Julie, as she will be moving on to new opportunities, as we announced a few weeks ago. At Acelia Pharma, we identify, develop, and commercialize novel drugs that address unmet medical needs across rare cancer conditions. We're based in Malmö, Sweden, and are listed on NASDAQ Stockholm. We have two drugs in our pipeline. Orviglans is a diagnostic drug that is now under FDA review with a Biduva date of July 3rd this year. We will spend the majority of this call talking about Orviglans. Oncoral is a patented tablet formulation of ibuprofen with encouraging results in phase one and potential to treat a range of solid tumors. We are very excited about OrbeGlance and here's why. OrbeGlance is addressing a well-defined unmet medical need for a subgroup of people living with cancer. This translates into an $800 million addressable global market opportunity, and OrbeGland is a first-in-class product to target this market and has orphan drug designation from the FDA. We have commercial scale manufacturing in place, and we have strong data from nine different clinical studies, including very compelling phase three ...